Key result
Tropomyosin isoforms detect bladder cancer with ~0.87 AUC, and high expression predicts poor survival.
Why the study?
The correlation between tropomyosin and clinical characteristics, as well as immune cell infiltration, in bladder cancer required investigation.
Does tropomyosin expression correlate with diagnosis, prognosis, and immune cell infiltration in bladder cancer?
Observational
Does tropomyosin expression correlate with diagnosis, prognosis, and immune cell infiltration in bladder cancer?
Effect estimate: AUC 0.845 (TPM1), 0.848 (TPM2), 0.873 (TPM3)
p-value: p=< 0.05
Tropomyosin isoforms TPM1 and TPM2 are potential diagnostic and prognostic biomarkers for bladder cancer, possibly linked to immune inhibition.
No takes yet. Share an insight, caveat, or question.
TM expression may link to bladder cancer features and immune infiltration; leaves open its value as a diagnostic or prognostic marker.
Yan et al. (2022) conducted an observational in Bladder cancer. Tropomyosin (TM) expression vs. Low expression / Low grade bladder cancer was evaluated on Diagnostic ability for bladder cancer (AUC 0.845 (TPM1), 0.848 (TPM2), 0.873 (TPM3), p=< 0.05). Tropomyosin isoforms TPM1, TPM2, and TPM3 demonstrated significant diagnostic ability for bladder cancer (AUCs 0.845, 0.848, and 0.873), and high TPM1/TPM2 expression predicted poor survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: